Navigation Links
BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
Date:5/3/2011

NOVATO, Calif., May 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 10, 2011 at 2:20 p.m. PT.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces First Quarter 2011 Financial Results
2. BioMarin to Present at the Deutsche Bank Healthcare Conference
3. BioMarin to Present at the Barclays Global Healthcare Conference
4. BioMarin to Present at the Cowen Health Care Conference
5. BioMarin to Present at the Citi Global Healthcare Conference
6. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
7. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
8. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
9. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
10. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
11. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 5, 2016 Research ... PET Imaging in Top 5 EU Markets"  report to their ... This report provides information on the current Positron Emission Tomography ... European Markets (T5 EU), which includes France ... , Spain and the ...
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... Yissum Research Development Company of the ... had signed an exclusive world-wide licensing and research agreement ... degradation and immunomodulatory drugs for cancer and immune dysfunction, ... first-in-class therapy for hematologic and solid malignancies. Financial terms ... novel technology was developed by Yinon Ben-Neriah , ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been ... presented by the American Institute of Architects and the Academy of Architecture for Health. ... Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC ... Stong is double board certified and the only facial plastic surgeon in Atlanta to ... Non-surgical therapies such as stem cells can be used to provide stabilization to hair ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week 2016, ... the United States to thank a nurse who's made a difference in their life. ... the American Red Cross of San Diego/Imperial Counties (up to $10,000) every time someone ...
(Date:5/5/2016)... Boston, MA (PRWEB) , ... May 05, 2016 , ... ... stress becomes a constant presence, it can weaken the immune system and increase inflammation, ... Ami B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts ...
(Date:5/5/2016)... PLAINSBORO, N.J. (PRWEB) , ... May 05, 2016 , ... ... on patients with cancer, today announced a new collaboration with Imerman Angels ... of cancer anywhere in the world. , “Imerman Angels provides an emotional lifeline to ...
Breaking Medicine News(10 mins):